# US 2012/0253160 A1 · Methods and Reagents for in Vivo Imaging of Cancel Cell Lines

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0253160 A1
- Document ID: US20120253160A1
- Status: Published application
- Kind: A1
- Application number: 13/439,279
- Filed: 2012-04-04
- Published: 2012-10-04
- Earliest claimed: 2006-03-23
- Assignees: Life Technologies Corporation
- Inventors: John Mauro; Thomas Steinberg; Julie Nyhus
- Web page: https://patentgrep.com/patent/US20120253160A1

## CPC

- G01N 33/5758: {involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites}
- A61K 49/0021: {the fluorescent group being a small organic molecule}
- A61K 49/0058: {Antibodies}
- G01N 33/532: Production of labelled immunochemicals
- G01N 33/54346: {Nanoparticles}
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Provided is reagents and methods for non-invasive in vivo imaging wherein the reagents comprise targeted carrier molecules conjugated to a NIB reporter molecule. In one aspect the targeted carrier molecule is an antibody, or fragment thereof that has specificity for an antigen in a living body, animal or human. In one embodiment the antibodes are anti-cancer/tumor marker antibodies, organ specific antibodies, tissue specific antibodies, cell type specific antibodies, cell surface specific antibodies, anti-viral antibodies, anti-bacterial antibodies and anti-pathogenic antibodies. The NIP reporter molecules are any fluorescent reporter molecule compatible with in vivo imaging and generally having an excitation wavelength of at least 580 nm.

## Claims

### Claim 1

A method for imaging a target antigen in a living body, wherein the method comprises;
a) providing a dye conjugate comprising a NIR dye and an antibody that binds to the target antigen;
b) introducing the dye conjugate into the body to form a contacted body;
c) illuminating the contacted body with an appropriate wavelength to form an illuminated body; and
d) observing the illuminated body wherein the target antigen is imaged;
wherein the target antigen is associated with cancer.

### Claim 2 (depends on 1)

The method of claim 1, wherein the target antigen is CEA (Carcinoembryonic Antigen).

### Claim 3 (depends on 1)

The method of claim 1, wherein the target antigen is selected from the group consisting of α2-Macroglobulin, α-Fetoprotein (AFP), β2-Microglobulin, β-Catenin, ACTH C terminal, ACTH N terminal, ACTR/AIB1, Alpha Fetoprotein, BCA-225, Bcl-2, BRCA2, Bromodeoxyuridine, CA 125, CA 15-3, CA 19-9, Calcitonin, Calretinin, Cathepsin D, CD15, CD63, CD74, CEA (Carcinoembryonic Antigen), Chorionic gonadotropin (β-subunit) (βHCG), Chromogranin A, c-Kit (CD 117), Cks1, Clathrin Antigen, Claudin-3, Claudin-4, Claudin-7, c-Met, c-Myc, Collagen Type IV, Collagen Type VII, COX-1, COX-2, Cyclin D1/D2 & D3, Cyclin E, Cytokeratin (Acidic or Basic), Cytokeratin (HMW), Cytokeratin 18, Cytokeratin 19, Cytokeratin 20, Cytokeratin ⅚, Cytokeratin 6, Cytokeratin 7, Cytokeratin 8, Cytokeratin 8/18, E2F-1, E-Cadherin, EGFr, EGP2 (Epithelial Glycoprotein 2), EMA (Epithelial Membrane Antigen), EMMPRIN, Enolase, EphB4 Receptor, ER (Estrogen Receptor), EZH2, Ezrin, FHIT, Galectin-1, Galectin-3, GCDFP-15, Glial Filament Acidic Protein, HER2 (c-erbB-2), HER4, HPV Early Protein, HPV16 Late I Protein, Human Epithelial Proliferating Ag, Human Epithelium Specific Ag, Human Milk Fat Globule Membrane, Human Milk Fat Globulin (HMFG1), Human Milk Fat Globulin (HMFG2), lnvolucrin, JAB1, Ki-67, Lewis A Ag, LRP/MVP, Major Vault Protein, MAP Kinase (ERK1+ERK2), MART-1 (Melan-A), MDM2, Melanoma Associated Antigen, Melanosome, Metallothionein, MGMT, MLH1, MSH2, MSH6, MTA1, MUC1 (Mucin 1), MUC2 (Mucin 2), MUC5AC, N-Cadherin, Neu-Oncogene, Nitric Oxide Synthase, Nucleophosmin/B23, NY-ESO-1, Occludin, p16, p21 (WAF1/Cip1), p27, p34, P53 Oncoprotein, Pancreatic Islet Cell Antibody, PARP, Paxillin, PD-ECGF, P-Giycoprotein (MDR), phospho-MAP Kinase (ERK1+2), Phosphotyrosine, Placental Alkaline Phosphatase, PR (Progesterone Receptor), PRL-3, PRLr, Proliferating Cell Protein Ki-67, pS2, PSA (Prostate Specific Antigen), PsAP (Prostatic Acid Phosphatase), PTEN, PTTG-1 (Pituitary Tumor Transforming Gene-1), Retinoblastoma Gene Product, SCLC (Small Cell Lung Cancer, CD56, N-CAM), Sialyl Lewis A, SKP2, Smad3, STAT3, TAG-72 (CA 72.4), TdT, Tenascin, Thyroglobulin, TIMP-2, Topo II, TS (Thymidylate Synthase), TTF-1 (Thyroid Transcription Factor 1), uPAR, Villine, Vmentin, Wtl (Wilm's tumor), and Z0-1.

### Claim 4 (depends on 1)

The method of claim 1, wherein the introducing step is non-invasive such that the integrity of the body is not disrupted.

### Claim 5 (depends on 1)

The method of claim 1, wherein the NIR dye has an excitation wavelength of about 580 nm to about 800 nm.

### Claim 6 (depends on 1)

The method of claim 1, wherein the NIR dye has an excitation wavelength of about 660 nm to about 790 nm.

### Claim 7 (depends on 1)

The method of claim 1, wherein the NIR dye is selected from the group consisting of a pyrene, an anthracene, a naphthalene, an acridine, a stilbene, an indole or benzindole, an xazole or benzoxazole, a thiazole or benzothiazole, a 4-amino-7-nitrobenz-2-oxa-1, 3-diazole (NBD), a carbocyanine, a carbostyryl, a porphyrin, a salicylate, an anthranilate, an azulene, a perylene, a pyridine, a quinoline, a borapolyazaindacene, a xanthene, an oxazine, a benzoxazine, a resorufin, a carbazine, a phenalenone, a coumarin, a benzofuran, a benzphenalenone and derivatives thereof.

### Claim 8 (depends on 1)

The method of claim 1, wherein the NIR dye is a semiconductor nanocrystal.

### Claim 9 (depends on 1)

The method of claim 1, wherein the NIR dye is impregnated in or associated with a microsphere.

### Claim 10 (depends on 1)

The method of claim 1, wherein the antibody is a monoclonal antibody.

### Claim 11 (depends on 1)

The method of claim 1, wherein the living body is a non-human vertebrate.

### Claim 12 (depends on 11)

The method of claim 11, wherein the living body is a mouse or rat.

### Claim 13 (depends on 1)

The method of claim 1, wherein the living body is a human.

### Claim 14 (depends on 1)

The method of claim 1, wherein the cancer is cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, colorectal carcinoma, pancreatic cancer, colon cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, rhabdosarcoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, astrocytoma, Kaposi's sarcoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, neuroblastoma, retinoblastoma, myeloma, lymphoma, or leukemia.

### Claim 15 (depends on 1)

The method of claim 1, wherein the introducing step comprises parenteral administration of the dye conjugate into the body.16.

### Claim 16 (depends on 1)

The method of claim 1, further comprising a step of:
incubating the contacted body for a period of time sufficient for the dye conjugate to contact the target antigen.

### Claim 17 (depends on 1)

The method of claim 1, wherein the period of time is at least 90 minutes.

### Claim 18 (depends on 1)

The method of claim 1, further comprising a step of:
transmitting data onto a computer processor, wherein the data represents the illuminated body; and
performing an analysis of the data with the computer processor to determine a result indicating the presence, amount or location of the target antigen.

### Claim 19 (depends on 18)

The method of claim 18, further comprising a display unit or printout which visually displays the result.

### Claim at position 20

20-26. (canceled)
